Naveen Pemmaraju, MD, completed his medical training at the University of Arkansas for Medical Sciences (UAMS), followed by a residency at Johns Hopkins University. He then completed both hematology and oncology training at the MD Anderson Cancer Center. Dr Pemmaraju remained at the MD Anderson Cancer Center as Assistant Professor in the Department of Leukemia and in 2017 was promoted to Associate Professor.
His research work has been focused on improving outcomes and developing novel therapies for patients with BPDCN, MPNs and AML. He has participated in several clinical trials, either as a principal investigator or co-investigator. Dr Pemmaraju was the lead researcher for the first ever allogeneic (“off the shelf”) CAR T-cell therapy specifically for patients with BPDCN.
Dr Pemmaraju had authored or co-authored over 129 publications, has presented his group’s research work at many national and international meetings, and continues to communicate the latest updates in the field through his active Twitter account, @doctorpemm. Reflecting this, he is now on the American Society of Hematology (ASH) Committee on Communications for 2020-23.